Brief: FDA Issues Approvable Letter For Seastar Medical’S Selective Cytopheretic Device For Pediatric Patients
30/10/2023 12:07
Oct 30 (Reuters) - SeaStar Medical Holding Corp ICU.O :
* FDA ISSUES APPROVABLE LETTER FOR SEASTAR MEDICAL’S
SELECTIVE
CYTOPHERETIC DEVICE FOR PEDIATRIC PATIENTS
* SEASTAR MEDICAL HOLDING CORP - EXPECTS TO COMMENCE
COMMERCIALIZATION OF SCD BY END OF 2023 OR Q1 OF 2024
Source text for Eikon: ID:nGNX7xQr41
Further company coverage: ICU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SeaStar Medical Holding
See all newsBrief: FDA Grants Seastar Medical Breakthrough Device Designation For Its Scd Therapy For The Treatment Of Hyperinflammation In Adult Patients With Sepsis Or A Septic Condition
SeaStar Medical Holding Corp reports results for the quarter ended June 30 - Earnings Summary
SeaStar Medical Q2 revenue jumps 82% on QUELIMMUNE demand
Brief: SeaStar Medical Q2 EPS USD -0.91
SeaStar Medical Holding Corp expected to post a loss of 97 cents a share - Earnings Preview